Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014 (2014), Article ID 798060, 6 pages
http://dx.doi.org/10.1155/2014/798060
Research Article

Patients with Ankylosing Spondylitis and Low Disease Activity because of Anti-TNF-Alpha Therapy Have Higher TRAIL Levels Than Controls: A Potential Compensatory Effect

1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, 39011 Santander, Spain
2Rheumatology Division, Hospital Lucus Augusti, 27003 Lugo, Spain
3Oncology Division, Hospital Del Bierzo, Ponferrada, 24411 León, Spain
4Rheumatology Division, Hospital General de Almansa, 02640 Albacete, Spain
5Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, IDIVAL, and CIBER Epidemiología y Salud Pública (CIBERESP), 39011 Santander, Spain
6Cardiology Division, Hospital Lucus Augusti, 27003 Lugo, Spain

Received 9 April 2014; Accepted 9 May 2014; Published 21 May 2014

Academic Editor: Vinod K. Mishra

Copyright © 2014 Fernanda Genre et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. González-Juanatey, T. R. Vázquez-Rodríguez, J. A. Miranda-Filloy et al., “The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease,” Medicine, vol. 88, no. 6, pp. 358–365, 2009. View at Publisher · View at Google Scholar
  2. S. Mathieu, P. Motreff, and M. Soubrier, “Spondyloarthropathies: an independent cardiovascular risk factor?” Joint Bone Spine, vol. 77, no. 6, pp. 542–545, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Heldmann, J. Brandt, I. E. van der Horst-Bruinsma et al., “The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab,” Clinical and Experimental Rheumatology, vol. 29, no. 4, pp. 672–680, 2011. View at Google Scholar · View at Scopus
  4. J. A. Miranda-Filloy, J. Llorca, B. Carnero-López, C. González-Juanatey, R. Blanco, and M. A. González-Gay, “TNF-α antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients,” Clinical and Experimental Rheumatology, vol. 30, no. 6, pp. 850–855, 2012. View at Google Scholar
  5. F. Genre, J. A. Miranda-Filloy, R. López-Mejías et al., “Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients,” Annals of the Rheumatic Diseases, vol. 72, no. 7, pp. 1265–1267, 2013. View at Google Scholar
  6. F. Genre, R. López-Mejías, J. A. Miranda-Filloy et al., “Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoyetin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy,” Clinical and Experimental Rheumatology, vol. 32, no. 2, pp. 231–236, 2014. View at Google Scholar
  7. J. A. Miranda-Filloy, R. López-Mejías, F. Genre et al., “Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy,” Clinical and Experimental Rheumatology, vol. 31, no. 3, pp. 365–371, 2013. View at Google Scholar
  8. F. Genre, R. López-Mejías, J. A. Miranda-Filloy et al., “Antitumour necrosis factor-α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients,” Annals of the Rheumatic Diseases, vol. 73, pp. 941–943, 2014. View at Publisher · View at Google Scholar
  9. F. Genre, J. A. Miranda-Filloy, R. López-Mejías et al., “Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy,” Clinical and Experimental Rheumatology, vol. 31, no. 4, pp. 532–537, 2013. View at Google Scholar
  10. F. Genre, R. López-Mejías, J. A. Miranda-Filloy et al., “Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy,” Clinical and Experimental Rheumatology, vol. 31, no. 5, pp. 749–755, 2013. View at Google Scholar
  11. F. Genre, R. López-Mejías, J. A. Miranda-Filloy et al., “Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy,” Clinical and Experimental Rheumatology, vol. 32, no. 2, pp. 218–224, 2014. View at Google Scholar
  12. F. Genre, R. López-Mejías, J. A. Miranda-Filloy et al., “Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-alpha antagonist therapy,” Clinical and Experimental Rheumatology. In press.
  13. A. M. van Sijl, I. C. van Eijk, M. J. Peters et al., “Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis,” Annals of the Rheumatic Diseases, 2013. View at Publisher · View at Google Scholar
  14. S. Bernardi, D. Milani, B. Fabris, P. Secchiero, and G. Zauli, “TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases,” Current Drug Targets, vol. 13, no. 9, pp. 1215–1221, 2012. View at Publisher · View at Google Scholar
  15. G. Brombo, S. Volpato, P. Secchiero et al., “Association of soluble Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) with central adiposity and low-density lipoprotein cholesterol,” PLoS ONE, vol. 8, no. 3, Article ID e58225, 2013. View at Google Scholar
  16. P. Secchiero, F. Corallini, A. P. Beltrami et al., “An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction,” Atherosclerosis, vol. 210, no. 1, pp. 274–277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Secchiero, E. Rimondi, M. G. di Lasio et al., “C-reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway,” Clinical Cancer Research, vol. 19, no. 8, pp. 1949–1959, 2013. View at Publisher · View at Google Scholar
  18. B. A. di Bartolo, S. P. Cartland, H. H. Harith, Y. V. Bobryshev, M. Schoppet, and M. M. Kavurma, “TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL,” PLoS ONE, vol. 8, no. 9, Article ID e74211, 2013. View at Google Scholar
  19. S. van der Linden, H. A. Valkenburg, and A. Cats, “Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria,” Arthritis and Rheumatism, vol. 27, no. 4, pp. 361–368, 1984. View at Google Scholar · View at Scopus
  20. M. A. Gonzalez-Gay, J. Llorca, M. T. Garcia-Unzueta et al., “High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 26, no. 4, pp. 596–603, 2008. View at Google Scholar · View at Scopus
  21. M. A. González-Gay, M. T. García-Unzueta, C. González-Juanatey et al., “Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 26, no. 2, pp. 311–316, 2008. View at Google Scholar
  22. M. A. Gonzales-Gay, M. T. Garcia-Unzueta, J. M. de Matias et al., “Influence of anti-TNF-α infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 24, no. 4, pp. 373–379, 2006. View at Google Scholar · View at Scopus
  23. D. van der Heijde, J. Sieper, W. P. Maksymowych et al., “2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 905–908, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Garrett, T. Jenkinson, L. G. Kennedy, H. Whitelock, P. Gaisford, and A. Calin, “A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index,” Journal of Rheumatology, vol. 21, no. 12, pp. 2286–2291, 1994. View at Google Scholar · View at Scopus
  25. M. N. Lub-De Hooge, E. G. E. de Vries, S. de Jong, and M. Bijl, “Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 64, no. 6, pp. 854–858, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Secchiero, F. Corallini, G. Castellino et al., “Baseline serum concentrations of TRAIL in early rheumatoid arthritis: relationship with response to disease-modifying antirheumatic drugs,” Journal of Rheumatology, vol. 37, no. 7, pp. 1461–1466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. Z.-X. Yang, L. Yan, W. Hao, Z. Ye, L. Chang, and R.-Q. Zhong, “Preliminary clinical measurement of the expression of TNF-related apoptosis inducing ligand in patients with ankylosing spondylitis,” Journal of Clinical Laboratory Analysis, vol. 22, no. 2, pp. 138–145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Kawano, K. Mori, M. Emoto et al., “Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 91, no. 3, pp. 316–320, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. S. E. Shoelson, J. Lee, and A. B. Goldfine, “Inflammation and insulin resistance,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1793–1801, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Robertson, M. J. Peters, I. B. McInnes, and N. Sattar, “Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm,” Nature Reviews: Rheumatology, vol. 9, no. 9, pp. 513–523, 2013. View at Publisher · View at Google Scholar
  31. M. A. González-Gay and C. González-Juanatey, “Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox,” Annals of the Rheumatic Diseases. In press.
  32. P. M. Ridker and N. Cook, “Clinical usefulness of very high and very low levels of C-reactive protein across the full range of framingham risk scores,” Circulation, vol. 109, no. 16, pp. 1955–1959, 2004. View at Publisher · View at Google Scholar · View at Scopus